Bukwang Pharmaceutical Co., Ltd. (KRX:003000)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,540.00
+40.00 (1.14%)
At close: Sep 8, 2025

Bukwang Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
Operating Revenue
179,163160,087125,928190,909182,491169,660
Upgrade
Other Revenue
-0--0-0--0
Upgrade
179,163160,087125,928190,909182,491169,660
Upgrade
Revenue Growth (YoY)
53.68%27.13%-34.04%4.61%7.56%0.87%
Upgrade
Cost of Revenue
98,16586,02379,012111,763106,94298,319
Upgrade
Gross Profit
80,99874,06446,91679,14775,55071,341
Upgrade
Selling, General & Admin
48,44845,96651,27449,79743,47745,373
Upgrade
Research & Development
20,37923,43134,55124,27422,46518,032
Upgrade
Other Operating Expenses
452.812,2252,0781,3451,3171,563
Upgrade
Operating Expenses
70,83972,44784,41379,37769,92867,313
Upgrade
Operating Income
10,1591,618-37,497-230.645,6224,028
Upgrade
Interest Expense
-6,490-6,490-3,808-1,760-1,408-1,515
Upgrade
Interest & Investment Income
4,4194,4193,0801,440268.161,313
Upgrade
Earnings From Equity Investments
-364.55343.13-1,50158.57-1,361-2,838
Upgrade
Currency Exchange Gain (Loss)
-64.59-64.59-177.4488.47322.31-2,105
Upgrade
Other Non Operating Income (Expenses)
-5,187-1,755867.73-113.7333.63-401.19
Upgrade
EBT Excluding Unusual Items
2,471-1,930-39,036-517.653,477-1,518
Upgrade
Impairment of Goodwill
-915.64-915.64----
Upgrade
Gain (Loss) on Sale of Investments
738.9738.9-564.4-567.4790.53-3,297
Upgrade
Gain (Loss) on Sale of Assets
53.7553.7530.6452.25220.0554.25
Upgrade
Asset Writedown
-8,670-8,670----3,539
Upgrade
Other Unusual Items
7,7537,753----
Upgrade
Pretax Income
1,432-2,970-39,569-1,0333,787-8,300
Upgrade
Income Tax Expense
-6,747489.25-5,1633,2166,5841,805
Upgrade
Earnings From Continuing Operations
8,179-3,459-34,407-4,249-2,797-10,105
Upgrade
Minority Interest in Earnings
180.65817.443,0771,7741,8802,902
Upgrade
Net Income
8,360-2,641-31,330-2,475-916.62-7,203
Upgrade
Net Income to Common
8,360-2,641-31,330-2,475-916.62-7,203
Upgrade
Shares Outstanding (Basic)
686868686869
Upgrade
Shares Outstanding (Diluted)
686868686869
Upgrade
Shares Change (YoY)
0.13%---0.01%-0.25%-4.24%
Upgrade
EPS (Basic)
122.06-38.59-457.67-36.15-13.39-104.95
Upgrade
EPS (Diluted)
121.64-39.00-458.00-36.15-13.39-105.00
Upgrade
Free Cash Flow
32,81132,424-12,19612,16325,740-1,194
Upgrade
Free Cash Flow Per Share
479.05473.65-178.17177.69375.98-17.40
Upgrade
Gross Margin
45.21%46.27%37.26%41.46%41.40%42.05%
Upgrade
Operating Margin
5.67%1.01%-29.78%-0.12%3.08%2.37%
Upgrade
Profit Margin
4.67%-1.65%-24.88%-1.30%-0.50%-4.25%
Upgrade
Free Cash Flow Margin
18.31%20.25%-9.69%6.37%14.11%-0.70%
Upgrade
EBITDA
14,8785,724-33,2044,88610,46510,186
Upgrade
EBITDA Margin
8.30%3.57%-26.37%2.56%5.73%6.00%
Upgrade
D&A For EBITDA
4,7194,1064,2925,1174,8436,158
Upgrade
EBIT
10,1591,618-37,497-230.645,6224,028
Upgrade
EBIT Margin
5.67%1.01%-29.78%-0.12%3.08%2.37%
Upgrade
Effective Tax Rate
----173.85%-
Upgrade
Advertising Expenses
-6,30712,76412,1816,6228,784
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.